Department of Nuclear Medicine/ Center for PET/CT, Zentralklinik Bad Berka, ENETS Center of Excellence, Zentralklinik Bad Berka, 99437 Bad Berka, Germany.
Theranostics. 2012;2(5):437-47. doi: 10.7150/thno.3645. Epub 2012 May 7.
The acronym THERANOSTICS epitomizes the inseparability of diagnosis and therapy, the pillars of medicine and takes into account personalized management of disease for a specific patient. Molecular phenotypes of neoplasms can be determined by molecular imaging with specific probes using positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or optical methods, so that the treatment is specifically targeted against the tumor and its environment. To meet these demands, we need to define the targets, ligands, coupling and labeling chemistry, the most appropriate radionuclides, biodistribution modifiers, and finally select the right patients for the personalized treatment. THERANOSTICS of neuroendocrine tumors (NETs) using Ga-68 labeled tracers for diagnostics with positron emission tomography/ computed tomography (PET/CT), and using Lu-177 or other metallic radionuclides for radionuclide therapy by applying the same peptide proves that personalized radionuclide therapy today is already a fact and not a fiction.
THERANOSTICS 这个缩写概括了诊断和治疗的不可分割性，是医学的两大支柱，并考虑了针对特定患者的疾病个体化管理。通过使用正电子发射断层扫描 (PET)、单光子发射计算机断层扫描 (SPECT)、磁共振成像 (MRI) 或光学方法的特定探针进行分子影像学，可以确定肿瘤的分子表型，从而使治疗针对肿瘤及其环境具有特异性。为了满足这些需求，我们需要定义靶点、配体、偶联和标记化学、最合适的放射性核素、生物分布修饰剂，最后为个体化治疗选择合适的患者。使用 Ga-68 标记示踪剂进行神经内分泌肿瘤 (NET) 的诊断，然后使用 Lu-177 或其他金属放射性核素进行放射性核素治疗，应用相同的肽证明了个体化放射性核素治疗如今已成为现实而非虚构。
